UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Pharmaceutical research, 2020-12, Vol.37 (12), p.252, Article 252

2020

Volltextzugriff (PDF)

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.1017-1028

2024

Volltextzugriff (PDF)

A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension

Journal of pharmacokinetics and pharmacodynamics, 2019-10, Vol.46 (5), p.499-509

2019

Volltextzugriff (PDF)

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB

CPT: pharmacometrics and systems pharmacology, 2023-07, Vol.12 (7), p.1029-1042

2023

Volltextzugriff (PDF)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

CPT: pharmacometrics and systems pharmacology, 2020-01, Vol.9 (1), p.48-59

2020

Volltextzugriff (PDF)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

Cancer reports, 2022-10, Vol.5 (10), p.e1578-n/a

2022

Volltextzugriff (PDF)

PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e44-e44

2024

Volltextzugriff (PDF)

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Journal of clinical pharmacology, 2021-12, Vol.61 (12), p.1579-1591

2021

Volltextzugriff (PDF)

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.751-767

2023

Volltextzugriff (PDF)

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

Clinical pharmacology and therapeutics, 2024-09

2024

Volltextzugriff (PDF)

A Disease Progression Model for Alzheimer’s Disease Predicts Longitudinal Trajectory of CDR-SB Score across different stages of the disease (2110)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.706-713

2010

Volltextzugriff (PDF)

Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease

British journal of clinical pharmacology, 2020-04, Vol.86 (4), p.801-811

2020

Volltextzugriff (PDF)

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Clinical pharmacology in drug development, 2021-10, Vol.10 (10), p.1142-1155

2021

Volltextzugriff (PDF)

Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

Journal of clinical pharmacology, 2008-08, Vol.48 (8), p.935-947

2008

Volltextzugriff (PDF)

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA-Naïve and ESA-Treated Chronic Kidney Disease Patients With Renal Anemia

Journal of clinical pharmacology, 2010-05, Vol.50 (5), p.507-520

2010

Volltextzugriff (PDF)

Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

Journal of clinical pharmacology, 2008-08, Vol.48 (8), p.934-947

2008

Volltextzugriff (PDF)

Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in French Nursing Homes: An Association between High Carriage Rate among Residents, Environmental Contamination, Poor Conformity with Good Hygiene Practice, and Putative Resident-to-Resident Transmission

Infection control and hospital epidemiology, 2014-04, Vol.35 (4), p.384-389

2014

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma

Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches

A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

A Disease Progression Model for Alzheimer’s Disease Predicts Longitudinal Trajectory of CDR-SB Score across different stages of the disease (2110)

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Model‐based approach for methoxy polyethylene glycol‐epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA-Naïve and ESA-Treated Chronic Kidney Disease Patients With Renal Anemia

Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in French Nursing Homes: An Association between High Carriage Rate among Residents, Environmental Contamination, Poor Conformity with Good Hygiene Practice, and Putative Resident-to-Resident Transmission

Aktive Filter

Suchergebnisse filtern